Latest Conference Articles

Patients with psoriatic arthritis and/or psoriasis reported improved BMI and HbA1C after 6 months of apremilast—with pronounced benefit among patients with obesity.

A comparison of monotherapy biologic or targeted synthetic DMARDs initiated in naive patients show each are beneficial for rheumatoid arthritis.

Data from the UPLIFT study show patients with psoriatic arthritis and their physicians see eye-to-eye on most subjects—except for treatment goals.

In this interview, de Benedetto discusses the major takeaways from her RAD 2023 conference presentation titled ‘New discoveries in the science of atopic dermatitis.’

In this interview segment, Chovatiya touched upon the late-breaking data he had presented at RAD 2023 conference on tapinarof cream 1% for younger eczema patients.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our April 2023 month-in-review features data on the association between social determinants of health and vision loss, preferences for AMD monitoring, and the launch of a new multimedia series.

At ARVO 2023, Schmidt-Erfurth discusses new insights regarding disease activity in GA, observing reductions in both RPE and photoreceptor degeneration after intravitreal pegcetacoplan therapy in the OAKS and DERBY trials.

In his RAD 2023 conference presentation, Chovatiya discussed data on recent therapies for eczema such as upadacitinib, ruxolitinib, tralokinumab, and dupilumab.

Bunick describes the key safety data from new late-breaking research on upadacitinib for atopic dermatitis that he presented at the Revolutionizing Atopic Dermatitis conference.

After new RAD 2023 data bolstered the evidence for lebrikizumab, clinicians are looking to see where the investigative drug may fit into the atopic dermatitis armamentarium.

Analysis of phase 3 trial data show about two-thirds of patients with atopic dermatitis who responded to the IL-13 inhibitor also saw benefit for difficult-to-treat hand and face eczema.

This segment of Abuabara’s Q&A interview involved a discussion of some of the other major points covered in her Revolutionizing Atopic Dermatitis presentation on long-term eczema control.

At ARVO 2023, Emanuelli discusses the primary analysis results of the phase 3 Pavilion trial evaluating the PDS with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema.

In this interview with Bunick, he describes some of the late-breaking research on upbadacitinib he presented at the the Revolutionizing Atopic Dermatitis conference.

In this Q&A interview with Abuabara, she discusses some of the major takeaways from her Revolutionizing Atopic Dermatitis presentation on long-term control of eczema.

At ARVO 2023, Elizabeth Rossin, MD, PhD, elaborates on genetic and biological pathways that may contribute to epiretinal membrane risk.

Some agents with unique mechanisms of action are nearing late-stage research for the treatment of eczema.

New phase 2 data from the SCRATCH-AD trial found that ruxolitinib 1.5% showed strong results for rapidly reducing itch in eczema patients, an improvement that continued over 28 days.

David Rosmarin, MD, reviews a quintet of promising agents advancing in late stages while at RAD 2023.

In this interview segment, Siegfried discussed the major points she hopes clinicians take away from her Revolutionizing Atopic Dermatitis conference talk regarding eczema in infants.

Late-breaking survey data from RAD 2023 show patients who achieve significant and quick response to itchy symptoms and lesion clearance are happier with their treatment regimen.

A retrospective study of nearly 19,000 eyes presented at ARVO 2023 found patients with GA lost 2 lines of vision at year 3 and are at meaningful risk of nAMD.

Contrary to short-term phase 3 research, the JAK-1 inhibitor was not dose-dependent nor less effective in older adult patients over nearly 2 years.

Siegfried spoke on the subjects covered in her presentation at the Revolutionizing Atopic Dermatitis conference, specifically the different conditions that can mirror eczema in infancy.

In her presentation at the Revolutionizing Atopic Dermatitis conference, Melinda Gooderham spoke about 4 specific upcoming therapies set to arrive this year for patients with eczema, including 2 nonsteroidal topicals.

At ARVO 2023, David Tabano, PhD, discussed the analysis of the largest real-world evaluation of treatment patterns and outcomes in DME patients treated with faricimab.

In this interview, King discussed his Revolutionizing Atopic Dermatitis presentation on his views about the safety of JAK inhibitors in otherwise healthy eczema patients.

Diamant Thaci, MD, reviewed the state of real-world biologic therapy use for moderate to severe atopic dermatitis during a session at RAD 2023.

During another interview segment, Silverberg highlighted some new insights into oral JAK-inhibitors from his presentation at the Revolutionizing Atopic Dermatitis conference.

In this interview segment, Silverberg discussed some of the major takeaways from his Revolutionizing Atopic Dermatitis presentation on eligibility for systemic treatments.